Flexion Therapeutics Inc (NASDAQ:FLXN)‘s stock had its “outperform” rating reaffirmed by Wells Fargo & Co in a note issued to investors on Saturday. They currently have a $30.00 target price on the specialty pharmaceutical company’s stock. Wells Fargo & Co’s target price would suggest a potential upside of 13.77% from the company’s previous close.

Several other research firms have also commented on FLXN. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $34.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 25th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $30.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 11th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $44.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 11th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 14th. Finally, BMO Capital Markets reaffirmed a “positive” rating and set a $33.00 target price on shares of Flexion Therapeutics in a report on Tuesday, February 7th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $28.68.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Shares of Flexion Therapeutics (NASDAQ:FLXN) traded down 2.19% on Friday, hitting $26.37. The stock had a trading volume of 322,925 shares. Flexion Therapeutics has a one year low of $8.16 and a one year high of $29.41. The company’s market cap is $836.75 million. The firm’s 50-day moving average is $24.28 and its 200-day moving average is $20.44.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Thursday, March 9th. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by $0.07. On average, analysts expect that Flexion Therapeutics will post ($3.50) EPS for the current fiscal year.

WARNING: “Flexion Therapeutics Inc (FLXN) Receives “Outperform” Rating from Wells Fargo & Co” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/04/21/flexion-therapeutics-inc-flxn-receives-outperform-rating-from-wells-fargo-co-updated-updated.html.

In related news, CFO Frederick W. Driscoll sold 3,000 shares of the stock in a transaction that occurred on Thursday, March 23rd. The stock was sold at an average price of $23.00, for a total value of $69,000.00. Following the completion of the transaction, the chief financial officer now directly owns 10,777 shares of the company’s stock, valued at approximately $247,871. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Neil Bodick sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $28.23, for a total value of $141,150.00. Following the completion of the sale, the insider now owns 46,137 shares of the company’s stock, valued at $1,302,447.51. The disclosure for this sale can be found here. Insiders sold a total of 18,000 shares of company stock valued at $407,950 over the last three months. Corporate insiders own 18.00% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in FLXN. Stoneridge Investment Partners LLC purchased a new stake in Flexion Therapeutics during the third quarter worth $271,000. Peregrine Capital Management LLC purchased a new stake in Flexion Therapeutics during the third quarter worth $14,126,000. Jennison Associates LLC purchased a new stake in Flexion Therapeutics during the third quarter worth $402,000. Alps Advisors Inc. increased its stake in Flexion Therapeutics by 15.8% in the third quarter. Alps Advisors Inc. now owns 35,084 shares of the specialty pharmaceutical company’s stock worth $686,000 after buying an additional 4,783 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Flexion Therapeutics by 2.3% in the third quarter. Bank of New York Mellon Corp now owns 1,631,323 shares of the specialty pharmaceutical company’s stock worth $31,876,000 after buying an additional 37,297 shares during the period. Hedge funds and other institutional investors own 62.25% of the company’s stock.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

5 Day Chart for NASDAQ:FLXN

Receive News & Stock Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related stocks with our FREE daily email newsletter.